Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Rhea-AI Summary

Phathom Pharmaceuticals (NASDAQ: PHAT) has appointed Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Cook brings extensive pharmaceutical legal experience, having previously served as Senior Vice President and General Counsel at Sage Therapeutics, with prior legal leadership positions at Aegerion, ViaCell, and Biogen. Her expertise spans corporate governance, commercial law, regulatory compliance, strategic transactions, and legal strategy. CEO Steven Basta emphasized Cook's potential impact on building Phathom into a leading GI company. Cook expressed enthusiasm about joining Phathom during its commercial evolution phase, highlighting the company's potential to transform acid-related GI disease treatment standards.

Positive

• Appointment of experienced legal executive with extensive pharmaceutical industry background
• Strategic addition to leadership team during commercial evolution phase
• Strengthened legal and corporate governance capabilities

Negative

• None.

FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary.

Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously served in legal leadership roles at Aegerion, ViaCell and Biogen.

“I’m delighted to welcome Anne Marie Cook to Phathom. Her experience and broad skills will be highly impactful as we work to build Phathom into a leading GI company in the coming years,” said Steven Basta, President and Chief Executive Officer of Phathom Pharmaceuticals. “Anne Marie will play a key role in shaping our corporate strategy.”

“I’m honored to join Phathom at such an exciting stage in its commercial evolution,” said Anne Marie Cook. “Phathom has the potential to redefine the standard of care in acid-related GI diseases, and I’m energized by the opportunity to contribute to the company’s next chapter and to help create value for patients, physicians, and shareholders.”

About Anne Marie Cook
Ms. Cook served as Senior Vice President, General Counsel, and Corporate Secretary at Sage Therapeutics (Nasdaq: SAGE) from 2015 to 2024. In this role, she was a member of the senior leadership team and led the legal activities across all aspects of the business, including commercialization, regulatory, compliance, intellectual property, and corporate governance. Prior to Sage, she served as General Counsel at Aegerion Pharmaceuticals and at ViaCell, where she also led business and corporate development functions. She previously held partner roles at Choate, Hall & Stewart and Miller, Canfield Paddock & Stone. Earlier in her career, she spent over a decade at Biogen, where she served as Vice President, Chief Corporate Counsel.

Ms. Cook earned her J.D. from Notre Dame Law School and holds a Bachelor of Science in Biology from Tufts University.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2025 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

Who is the new Chief Legal Officer of Phathom Pharmaceuticals (PHAT)?

Anne Marie Cook, J.D., who previously served as Senior Vice President and General Counsel at Sage Therapeutics, has been appointed as Chief Legal Officer and Corporate Secretary of Phathom Pharmaceuticals.

What is Anne Marie Cook's background before joining Phathom Pharmaceuticals (PHAT)?

Cook held legal leadership positions at several pharmaceutical companies, including serving as Senior Vice President and General Counsel at Sage Therapeutics, and previous roles at Aegerion, ViaCell, and Biogen.

What areas of expertise does Anne Marie Cook bring to Phathom Pharmaceuticals?

Cook brings expertise in corporate governance, commercial law, regulatory compliance, strategic transactions, and legal strategy to Phathom Pharmaceuticals.

What is Phathom Pharmaceuticals' (PHAT) main business focus?

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases.